Correction of the Nonlinear Dose Response Improves the Viability of Adenoviral Vectors for Gene Therapy of Fabry Disease
Robin J. Ziegler, Seng H. Cheng(Pfizer (United States)), Yiannis A. Ioannou(Icahn School of Medicine at Mount Sinai), Nelson S. Yew, Chester Li, Nico van Rooijen(Institute of Immunology), Robert J. Desnick(Icahn School of Medicine at Mount Sinai), Mark A. Goldberg(Brigham and Women's Hospital), Yunxiang Zhu(SynZyme Technologies (United States)), Maribeth Cherry, Donna Hempel
Cited by 46
Related Papers
Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C–dependent buffering mechanism
|Nature Medicine|2009|957
MHC class II–dependent basophil–CD4+ T cell interactions promote TH2 cytokine–dependent immunity
|Nature Immunology|2009|590
Agalsidase-Beta Therapy for Advanced Fabry Disease
|Annals of Internal Medicine|2007|565
Acid sphingomyelinase deficient mice: a model of types A and B Niemann–Pick disease
|Nature Genetics|1995|477